Patents Examined by Zinna Northington Davis
  • Patent number: 10807959
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 20, 2020
    Assignee: Vanderbilt University
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • Patent number: 10807993
    Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: October 20, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume
  • Patent number: 10800741
    Abstract: The present invention relates to a quinoline compound, as well as a preparation method and medical use therefor. Specifically, the present invention relates to a novel quinolone compound represented by the general formula (I) and a method for preparing the same, as well as a use therefor as an inhibitor for a plurality of protein kinases, and a use in the prevention and/or treatment of cancer in particular; the definition of each group in the general formula (I) is the same as the definition in the description.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: October 13, 2020
    Assignee: Ancureall Pharmaceutical (Shanghai) Co., Ltd.
    Inventors: Jutong Si, Meifeng Jiang, Jiayan Li, Han Zeng, Huabin Yang
  • Patent number: 10800761
    Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: October 13, 2020
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
  • Patent number: 10800733
    Abstract: Disclosed are a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the Formula I, and an application thereof in preparing drugs for regulating blood lipids.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 13, 2020
    Assignee: Shanghai Bioenergy Medicine Science & Technology Co., Ltd.
    Inventors: Yuqiong Dong, Quanhai Liu, Yu Shen, Wentao Cai
  • Patent number: 10792292
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 6, 2020
    Assignee: Propella Therapeutics, Inc.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • Patent number: 10793579
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 6, 2020
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Patent number: 10793574
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 6, 2020
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 10787447
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R1, R2 and R4 are as defined herein.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 29, 2020
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • Patent number: 10787472
    Abstract: The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: September 29, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
  • Patent number: 10781207
    Abstract: The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: September 22, 2020
    Assignee: IsoCure Biosciences Inc.
    Inventors: Tinghu Zhang, Jianwei Che
  • Patent number: 10781172
    Abstract: Disclosed are complexes and methods of using the complexes as catalysts for addition of amines to unsaturated electrophiles, as well as novel compounds produced by the disclosed complexes and methods. The disclosed methods may utilize the disclosed complexes as catalysts for adding unprotected primary amines and secondary amines to unsaturated electrophiles in an enantioselective manner to produce novel compounds which may include amino substituted succinimide compounds.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 22, 2020
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Brice Uno
  • Patent number: 10774058
    Abstract: A process for preparing D-glucaro-6,3-lactone from a salt of D-glucaric acid is provided. The process includes: adding a mineral acid to a pre-cooled solution including a salt of D-glucaric acid, water, and acetone to obtain a crude mixture; allowing the crude mixture to rise to a temperature in a range of ?15° C. to ?35° C. and stirring the crude mixture; filtrating the crude mixture and washing with an acetone and water solvent mixture to obtain a filtrate; concentrating the filtrate under vacuum pressure to obtain a concentrated filtrate having a water content in a range of ?20.0 wt. % to ?40.0 wt. %, relative to an overall weight of the concentrated filtrate; storing the concentrated filtrate at a temperature in a range of ?0° C. to ?5° C., and optionally repeating the concentrating and storing steps to obtain a precipitate comprising D-glucaro-6,3-lactone.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: September 15, 2020
    Assignee: BASF SE
    Inventors: Abhijeet Roy, Dominik Ohlmann, Rahul Mulay, Priti Kulkarni, Vijay Narayanan Swaminathan
  • Patent number: 10774046
    Abstract: Some embodiments of the invention include inventive compounds. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Other embodiments include PFKFB4 inhibitors and methods of using the same that can target neoplastic cells, including, such as, mechanisms within those cells that relate to the use of the glycolytic pathway. In other embodiments, small molecule PFKFB4 inhibitors are used to disrupt the kinase domain of PFKFB4 and, in some instances, decrease the glucose metabolism and growth of human cancers.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 15, 2020
    Inventors: Sucheta Telang, Jason Chesney, John O. Trent, Joseph A. Burlison, Nagaraju Miriyala
  • Patent number: 10774093
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 15, 2020
    Assignee: Taxis Pharmaceuticals, Inc.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit S. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • Patent number: 10774043
    Abstract: The present invention discloses compounds of Formula I, wherein each of R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from H, OBn, OH, CH2OBn, CH2OH, CH3; R9 is selected from alkyl, substituted alkyl, hydroxyl alkyl, alkenyl, benzyl; process for preparation of N-alkylated glycolactam compounds of Formula I and their use for the synthesis of piperidine alkaloids and their analogues.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 15, 2020
    Inventors: Asish Kumar Bhattacharya, Hemender Rami Chand
  • Patent number: 10766885
    Abstract: A compound having the formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: September 8, 2020
    Inventors: Xingke Ju, Chengyuan Liang, Bin Tian, Yuzhi Liu, Lei Tian, Gennian Mao, Limei Wang, Yuanyuan He, Yongbo Wang, Jingwen Xu, Dan Yang, Liang Qi, Wenbo Yao, Qianqian Zhao, Han Li
  • Patent number: 10766909
    Abstract: The present invention relates to a process for preparing halogenated pyridine derivatives of the formula (II) proceeding from compounds of the formula (I) via intermediates of the formula (IIIa) or (IIIb) where the radicals Q and W are each independently halogen, R2 is halogen or —O-pivaloyl, and Y is halogen, CO2R1 or NO2, where R1 is (C1-C6)-alkyl or (C1-C6)-haloalkyl.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: September 8, 2020
    Assignee: Bayer CropScience Aktiengesellschaft
    Inventors: Marc Mosrin, Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Nina Kausch-Busies, David Wilcke, Matthieu Willot
  • Patent number: 10759760
    Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 1, 2020
    Inventors: René Martin, René Smits, Ronny Hesse, Alexander Hoepping, Marco Müller, Sandra Hübner
  • Patent number: 10759759
    Abstract: Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 1, 2020
    Assignee: BioCryst Pharmaceuticals, inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Venkat R. Chintareddy, Weihe Zhang, Lakshminarayana Vogeti